UPDATE 1-U.S. FDA approves Bristol-Myers immunotherapy for lung cancer

March 4 (Reuters) - U.S. health regulators on Wednesday swiftly approved a Bristol-Myers Squibb Co drug that helps the immune system fight the most common form of lung cancer, sending the company's shares up more than 5 percent to a multi-year high.